The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
1 other identifier
interventional
29
1 country
1
Brief Summary
The aim of the study is to test the following hypotheses:
- 1.that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease.
- 2.if an abnormal function of the principal cells is present in autosomal dominant polycystic kidney disease, this will become more pronounced at high and low sodium intake.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2006
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 10, 2006
CompletedFirst Posted
Study publicly available on registry
December 12, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2011
CompletedMarch 20, 2018
March 1, 2018
4 years
December 10, 2006
March 16, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
u-AQP-2CR
Urinary Aquaporin-2 corrected for creatinine
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
Secondary Outcomes (8)
u-ENaC (beta)CR
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
FENa
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
CH2O
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
u-cAMP
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
uPGE-2
Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
- +3 more secondary outcomes
Study Arms (4)
Patients with ADPKD, HS
OTHEREach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
Patients with ADPKD, LS
OTHEREach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
Healthy Control Subjects, HS
OTHEREach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
Healthy Control Subjects, LS
OTHEREach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
Interventions
7 ml/ kg of 3% saline were given over 30 minutes.
Eligibility Criteria
You may qualify if:
- Caucasian men and women
- age 18-65 years
- BMI between 18,5-30,0 kg/m2
- ADPKD, diagnosed by the following findings on ultra scan:
- for patients without ADPKD family history: \> 5 bilateral cysts
- for patients with ADPKD family history: \< 30 years: 2 cysts (unilateral or bilateral) 30-60 years: 2 or more bilateral cysts \> 60 years: 4 or more bilateral cysts
- Kidney function: stadium 1-4.
You may not qualify if:
- Other kidney disease
- Anamnestic or clinical signs of acute myocardial infarction, atrial fibrillation, heart valve disease or chronic heart failure
- Anamnestic or clinical signs of disease in lungs, liver,endocrine organs or brain or neoplastic disease
- Family history of rupture of intracerebral aneurisms
- Alcohol or drug abuse
- Smoking
- Medical treatment arat form antihypertensives and oral anticonceptives
- Pregnancy or breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Medical Research, Holstebro Hospital
Holstebro, 7500, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Erling B. Pedersen, Professor
Department of Medical Research, Holstebro Hospital, Denmark
- PRINCIPAL INVESTIGATOR
Carolina C. Graffe, MD
Department of Medical Research, Holstebro Hospital, Denmark
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator, PhD, MD
Study Record Dates
First Submitted
December 10, 2006
First Posted
December 12, 2006
Study Start
October 1, 2006
Primary Completion
October 1, 2010
Study Completion
November 1, 2011
Last Updated
March 20, 2018
Record last verified: 2018-03